The present patent application relates to 11.beta.-benzaldoxime derivatives of D-homooestra-4,9-dien-3-ones of formula I: ##STR00001## wherein R.sub.1 is a hydrogen atom or a C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-acyl, C.sub.1-C.sub.4-alkoxycarbonyl, C.sub.1-C.sub.4-alkylthiocarbonyl, C.sub.1-C.sub.6-alkylaminocarbonyl or arylaminocarbonyl group; and R.sub.2 is a hydrogen atom or a C.sub.1-C.sub.6-alkyl or C.sub.1-C.sub.6-acyl group.Compounds of formula I bind more strongly to the glucocorticoid receptor than to the progesterone receptor and are effective antiglucocorticoids. According to the invention, they are suitable for the treatment and/or prevention of symptoms and/or diseases that are attributable to an androgen deficiency induced by glucocorticoids, especially cortisol.